The Stem Cell Therapeutic and Research Reauthorization Act of 2026, usually shortened to the Stem Cell Reauthorization Act, moved twice this summer, and patients keep asking whether it changes anything for adipose tissue. It does not. S. 4109 is still pending, and the two programs it would extend involve donated bone marrow and umbilical cord blood, not fat.
TLDR: S. 4109 has not passed. The Senate HELP Committee reported it with an amendment on June 22, 2026, and it sits on the Senate calendar as Calendar No. 443. The House companion, H.R. 5160, passed the House by voice vote on July 20, 2026. If enacted, the bill would reauthorize the C.W. Bill Young Cell Transplantation Program and the National Cord Blood Inventory through fiscal year 2031. It says nothing about adipose tissue. Banking your own fat does not guarantee eligibility, access, or any future clinical benefit.
Important Disclaimer: Save My Fat is a connector linking patients and providers to a United States tissue bank. Save My Fat does not provide FDA-approved treatments or cures and does not guarantee eligibility, access, or clinical benefit. Adipose tissue and stromal vascular fraction are investigational and are not FDA approved. This article covers pending federal legislation for educational purposes only and is not legal advice. Patients should consult their own licensed healthcare professionals before making any decision.
A bill with the words stem cell in its title moved twice in five weeks. Advocacy emails went out, and some clinic pages began citing federal momentum. Patients researching fat banking asked whether their odds had shifted.
The answer is no, for two reasons. The bill has not passed, so nothing in it is settled law. More importantly for this audience, it never mentions adipose tissue anywhere.
What the Stem Cell Reauthorization Act Would Actually Do
S. 4109 was introduced in the 119th Congress on March 17, 2026 by Sen. Jack Reed of Rhode Island, with original cosponsors Sen. Tim Scott, Sen. Tina Smith, and Sen. James Lankford. It would reauthorize two existing federal programs through fiscal year 2031: the C.W. Bill Young Cell Transplantation Program and the National Cord Blood Inventory.
The subjects recorded for the bill are blood and blood diseases, cell biology and embryology, and organ and tissue donation and transplantation. Both programs involve donated blood-forming cells from bone marrow and umbilical cord blood. HRSA publishes the legislative history for these programs.
People searching for national marrow donor program funding often land on coverage of this bill, because the federal marrow and cord blood world blurs together in news write-ups. A reauthorization decides how long a program stays authorized, nothing more.
Where S. 4109 Stands Right Now
Status matters more than substance here, because a bill on a calendar is not a law. The Senate finished committee work in June, and the House moved a companion in July.
| Step | S. 4109 (Senate) | H.R. 5160 (House) |
|---|---|---|
| Sponsor | Sen. Jack Reed (D-RI) | Rep. Christopher H. Smith (R-NJ-4) |
| Key action | Ordered reported favorably with a substitute, June 17, 2026 | Passed the House by voice vote under suspension, July 20, 2026 |
| Latest step | Reported with amendment, placed on the calendar June 22, 2026, Calendar No. 443 | Received in the Senate, placed on the calendar July 21, 2026, Calendar No. 464 |
| Status on July 27, 2026 | Pending | Pending in the Senate |
A voice vote records no individual tally. Calendar placement means the Senate may take the bill up, not that it has.
Why the Bill Has Nothing to Do With Adipose Tissue
The phrase stem cell covers cell families that behave nothing alike. Blood-forming cells from marrow and cord blood are used in transplant medicine. Cells derived from fat are mesenchymal stromal cells, in a different regulatory position entirely.
The FDA is direct about approval status. Its consumer alert on regenerative products states that blood-forming stem cells from cord blood are the only approved stem cell products and that no exosome product is FDA approved.
The one approved mesenchymal product makes the same point. Ryoncil, approved December 18, 2024 as the first FDA-approved mesenchymal stromal cell therapy, is allogeneic and bone marrow derived, indicated only for steroid-refractory acute graft versus host disease in pediatric patients 2 months of age and older, per the FDA’s Ryoncil product page.
So a bill extending funding authority for marrow and cord blood programs cannot create an adipose pathway. It classifies nothing and approves nothing.
Why patients assume otherwise
Search results and news feeds compress stem cell into one idea, and marketing sometimes borrows federal legitimacy that was never extended. The FTC expects health claims to rest on competent and reliable scientific evidence, a standard set out in its Health Products Compliance Guidance. A clinic citing pending legislation to support an unapproved product is a warning sign.
Approved Transplant Programs Versus the Investigational Adipose Space
The distinction that matters is between a federally funded transplant program serving approved indications and an investigational space where nothing is approved yet. One has established clinical use behind it, and the other is research with unfinished answers.
| Question | Marrow and cord blood programs | Adipose-derived cells |
|---|---|---|
| Role of S. 4109 | Reauthorization through fiscal year 2031 | No effect at all |
| FDA status | Blood-forming cord blood cells are the only approved stem cell products | No approved product, and use is investigational |
| Setting | Transplant medicine for blood diseases | Registered trials, or narrow 21 CFR 1271.10(a) uses |
| Patient expectation | Care decided by a transplant team | Eligibility, access, and benefit cannot be guaranteed |
Those four criteria appear in 21 CFR 1271.10(a), and the FDA explains both product categories in its tissue product questions and answers. Facility duties follow from that split, which is why FDA establishment registration matters for any bank.
Evidence in the adipose space also remains preliminary. The published ADIPOA2 results for autologous adipose-derived cells in knee osteoarthritis reported that a single injection did not significantly improve pain and function. Decisions belong with a licensed provider who knows your history.
Three Separate Layers That People Keep Merging
Federal authorization, FDA product regulation, and state practice law run on separate tracks. S. 4109 sits in the first, deciding how long two programs stay authorized. The FDA occupies the second, deciding what a product is and what evidence it needs. States occupy the third, setting notice and consent duties, so reviewing the state stem cell laws where you live is worthwhile.
Right to Try laws address whether certain patients may seek an investigational product, not whether it has been approved. Movement in one layer does not create approval in another.
What Would Change If S. 4109 Becomes Law
If both chambers pass identical text and the President signs it, the two named programs would carry authorization through fiscal year 2031. That matters for transplant medicine.
What would not change is everything governing adipose tissue. 21 CFR Part 1271 would read the same, no adipose-derived product would become approved, and state notice and consent duties would stand untouched.
Frequently Asked Questions
What does the federal reauthorization act actually fund and regulate?
S. 4109 would reauthorize the C.W. Bill Young Cell Transplantation Program and the National Cord Blood Inventory through fiscal year 2031. Reauthorization sets how long a program stays authorized. The bill does not classify products, approve therapies, or set clinic standards for any provider.
Has S. 4109 passed and become law?
No. As of July 27, 2026 it is pending. The Senate HELP Committee ordered it reported favorably with a substitute on June 17, 2026, and it was reported with an amendment and placed on the Senate calendar on June 22, 2026 as Calendar No. 443. The House companion H.R. 5160 passed by voice vote on July 20, 2026.
Does this bill apply to adipose-derived stem cells?
It does not. Nothing in S. 4109 addresses adipose tissue, stromal vascular fraction, or adipose-derived cells. Those remain investigational, with no FDA-approved product available. If the bill becomes law, the position of fat-derived cells will be unchanged, and any future use will still depend on FDA pathways and physician judgment.
What is the C.W. Bill Young Cell Transplantation Program?
It is the federal program named in the bill covering donated blood-forming cells used in transplant medicine, drawn from bone marrow and umbilical cord blood. The National Cord Blood Inventory is the cord blood component. Both involve donor-based transplantation, a separate field from investigational work on a patient’s own fat.
How is this different from state-level stem cell laws?
State laws regulate licensed practice. Several require patient notices, written consent, and particular sourcing or testing standards before a provider may offer a therapy that is not FDA approved. Federal reauthorization does none of that. A state can impose duties on your physician while this bill says nothing about you.
Where can patients track this bill’s progress in Congress?
Follow the calendar status of both S. 4109 and H.R. 5160, since either chamber can act next. HRSA also maintains a legislation page for these programs. Be careful with secondhand summaries, because coverage often describes committee action as passage, which is how a pending bill starts to sound like settled law.
Key Takeaways
The Stem Cell Therapeutic and Research Reauthorization Act of 2026 is pending, not passed. It cleared the Senate HELP Committee with an amendment on June 22, 2026 and sits as Calendar No. 443, while the House companion H.R. 5160 passed by voice vote on July 20, 2026. If enacted, it would extend authorization for the C.W. Bill Young Cell Transplantation Program and the National Cord Blood Inventory through fiscal year 2031.
Those are bone marrow and umbilical cord blood transplant programs with no connection to adipose tissue. The wider lesson holds for every headline here: federal funding decisions, FDA product classification, and state practice laws move on separate tracks, and momentum in one does not create approval in another. Adipose-derived cells stay investigational, the evidence stays preliminary, and decisions belong with a licensed provider.
Save My Fat operates as a tissue preservation service, not a medical practice or treatment provider. Stem cell and regenerative medicine regulations vary by state, including specific informed-consent and disclosure requirements in Florida, Utah, and Nevada governing tissue and stem cell services. Banking adipose tissue does not connect patients to any treatment pathway, and any future use depends on FDA regulatory status, physician guidance, and the availability of approved or investigational pathways at that time.
If you are weighing adipose tissue banking for potential future use, base the decision on current regulation rather than pending bills. Current pricing is listed on the pricing page, and questions can go to the Save My Fat team first.
Save My Fat partners with a U.S.-based tissue bank for laboratory processing and storage.
This article is for educational purposes only and does not constitute medical or legal advice. Save My Fat is an education and connector service, not a medical practice, and clinical review by qualified professionals in neurology and neurosurgery is required before publication. Adipose tissue and adipose-derived cells are investigational and are not FDA approved. Please consult your neurologist or neurosurgeon before making any decisions about tissue banking, investigational pathways, or your medical care.
About the author: Oscar Tellez is the founder and CEO of Save My Fat. He holds a Bachelor of Science in Exercise Science and Health Promotion from Florida Atlantic University. He has spent more than a decade in the regenerative medicine industry across product distribution, laboratory and vendor relationships, and provider training. He is not a licensed clinician, and this article is educational, not medical advice.
Related guide: FDA adipose tissue regulation.
